Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Oh on Results of Chemotherapy Versus ARTA in Prostate Cancer

February 17th 2017

William Oh, MD, professor, Mount Sinai Hospital, discusses the results from a trial that compared second-line chemotherapy to alternative androgen receptor-targeted agents (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Josh Armenia on Results of Mutated Gene Analysis in Prostate Cancer

February 17th 2017

Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the results of an analysis of significantly mutated genes in prostate cancer.

Dr. Dreicer on Future Treatment Approaches in Prostate Cancer

February 17th 2017

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses the progress he would like to see accomplished in the field of metastatic castration-resistant prostate cancer.

Phase III Results Support Novel Focal Therapy for Low-Risk Prostate Cancer

February 16th 2017

Padeliporfin vascular-targeted photodynamic therapy, a novel tissue-preserving treatment, may offer men with low-risk prostate cancer a safe and effective alternative to either active surveillance or radical therapy, according to the results of a phase III trial.

Dr. Buffington on MRI Fusion for Prostate Cancer

February 15th 2017

Philip J. Buffington, MD, chief medical officer, The Urology Group, discusses MRI fusion-guided biopsy in patients with prostate cancer.

Circulating Tumor DNA Can Advance Personalized Care in mCRPC

February 14th 2017

Up to 94% of patients with metastatic castration-resistant prostate cancer have circulating tumor DNA with at least 1 genetic alteration, suggesting ctDNA could be a noninvasive alternative to traditional tumor biopsies and help personalize treatment in this setting.

Dr. Albala on Patient Selection for Robotic Surgery in Prostate Cancer

February 9th 2017

David Albala, MD, urologist and medical director, Associated Medical Professionals, discusses patients with prostate cancer who are best suited to be treated with robotic surgery.

Dr. Scher on Promise of Liquid Biopsies in Prostate Cancer

February 8th 2017

Howard I. Scher, MD, chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential that liquid biopsies will have in the treatment landscape of prostate cancer.

Dr. Harris on PSA Testing and Active Surveillance in Prostate Cancer

February 7th 2017

Richard Harris, MD, urologist, UroPartners, discusses the respective roles of PSA testing and active surveillance in the treatment of patients with prostate cancer.

Adding Antiandrogen Therapy to Radiation Improves Survival in Recurrent Prostate Cancer

February 6th 2017

The addition of hormonal therapy to radiation treatment following surgery significantly improved survival in patients with recurrent prostate cancer, according to the results of a study published in The New England Journal of Medicine.

Dr. Abida on Future of Hormonal Therapy in Prostate Cancer

February 2nd 2017

Wassim Abida, MD, PhD, Memorial Sloan Kettering Cancer Center, discusses the future of hormonal therapy in prostate cancer.

New Marker May Identify Men Who Require More Aggressive Prostate Cancer Treatment

January 27th 2017

A prostate-specific antigen nadir greater than 0.5 ng/mL following radiation and androgen deprivation therapy seems to identify men prior to PSA failure who are at high-risk for death, and would thus require more aggressive treatment for their prostate cancer.

Dr. Kantoff on Docetaxel Plus Androgen Deprivation Therapy in Prostate Cancer

January 26th 2017

Philip W. Kantoff, MD, chair of the Department of Medicine, Memorial Sloan Kettering Cancer Center and a 2014 Giants of Cancer Care winner for Genitourinary Cancer, discusses the combination of docetaxel (Taxotere) chemotherapy and androgen deprivation therapy (ADT) in the setting of metastatic hormone-sensitive prostate cancer.

Dr. Rathkopf on AR-V7 Biomarker in Prostate Cancer

January 26th 2017

Dana E. Rathkopf, MD, Memorial Sloan Kettering Cancer Center, discusses the emergence of the androgen receptor splice variant-7 (AR-V7) biomarker in the treatment of patients with prostate cancer.

Dr. Stein on AR-Resistance in Prostate Cancer

January 25th 2017

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses androgen receptor–resistance in prostate cancer.

Robotic Surgery Is Milestone Advancement for Prostate Cancer Treatment

January 23rd 2017

David Albala, MD, discusses the uses and benefits of robotic urological surgery in prostate cancer, as well as methods to achieve better physician compliance.

Dr. Harris on Controversy of PSA Testing for Prostate Cancer

January 21st 2017

Richard Harris, MD, urologist, UroPartners, discusses PSA testing for patients with prostate cancer and the controversial grade D recommendation of the United States Task Force.

Dr. Oh on Remaining Challenges With Docetaxel in Prostate Cancer

January 20th 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the challenges that remain with the use of docetaxel to treat patients with prostate cancer.

Dr. Olsson on Differences Between LHRH Agonists and Antagonists in Prostate Cancer

January 19th 2017

Carl Olsson, MD, Integrated Medical Professionals, compares the efficacy of LHRH agonists with antagonists, which are commonly used to treat patients with prostate cancer.

Prostate Cancer Treatment Rates Drop Following Changes in Screening Recommendations

January 19th 2017

A sharp decline has been observed in the overall rate of men receiving treatment for prostate cancer.

NEXT PAGE
PREVIOUS PAGE